Most Read Articles
Pearl Toh, 6 days ago
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Roshini Claire Anthony, 05 Jan 2018

The addition of daratumumab to a bortezomib-melphalan-prednisone (VMP) regimen appears to improve progression-free survival (PFS) over VMP alone in individuals newly diagnosed with multiple myeloma who are ineligible for stem-cell transplantation, according to findings from the phase III ALCYONE* trial.

01 Jan 2012
A phase III, open-label, single-centre study presents the suitability of DTaP-IPV//PRP-T booster following primary vaccination with DTaP-IPV-Hep B-PRP-T vaccine.
Roshini Claire Anthony, 23 hours ago

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

Most patients on ARNI do not receive full dose

10 Jan 2018

Most patients on the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan are started on the lowest dose and remain on the lowest or intermediate dose of the drug, data from primary care and cardiology practices in Germany have shown. [Wachter R, et al, AHA 2017, poster S5001]

Researchers retrospectively reviewed data from 1,095 primary care practices and 43 cardiology practices in Germany. The data set comprised a total of 1,643 patients prescribed sacubitril/valsartan, of whom 1,041 patients were from primary care practices and 692 were from cardiology practices.

Two-thirds of the patients (64 percent of the primary care cohort, 66 percent of the cardiology cohort) were started on the lowest dose of sacubitril/valsartan (26/24 mg BID). Among these patients, only 36 percent of those from the primary care cohort and 41 percent of those from the cardiology cohort had their sacubitril/valsartan dose up-titrated during a maximum follow-up period of 12 months. However, less than 11 percent of the patients received the target dose (103/97 mg BID) at the last recorded prescription.

Less than one-third of the patients (30 percent of the primary care cohort, 26 percent of the cardiology cohort) were initiated on the recommended starting dose of sacubitril/valsartan (51/49 mg BID). Among these patients, 24 percent of those from the primary care cohort and 36 percent of those from the cardiology cohort had their dose up-titrated to the target dose.

Only a small proportion (10 percent) of patients in each prescription group had their sacubitril/valsartan dose down-titrated.

Following the initiation of sacubitril/valsartan, the patients’ N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels decreased by approximately 30 percent (-503 pg/mL) – similar to the reduction observed in the PARADIGM-HF study.

Significant decreases in HbA1c (-0.3 percent; p<0.001) and systolic and diastolic blood pressure (-3.4 mm Hg and -1.6 mm Hg, respectively; p<0.001) were also observed following sacubitril/valsartan initiation. New York Heart Association class remained stable over time in the majority of patients.

“The effect of treatment with sacubitril/valsartan may have been greater if all patients had received the target dose,” the researchers suggested.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Roshini Claire Anthony, 05 Jan 2018

The addition of daratumumab to a bortezomib-melphalan-prednisone (VMP) regimen appears to improve progression-free survival (PFS) over VMP alone in individuals newly diagnosed with multiple myeloma who are ineligible for stem-cell transplantation, according to findings from the phase III ALCYONE* trial.

01 Jan 2012
A phase III, open-label, single-centre study presents the suitability of DTaP-IPV//PRP-T booster following primary vaccination with DTaP-IPV-Hep B-PRP-T vaccine.
Roshini Claire Anthony, 23 hours ago

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.